No, p53 is not an oncogene. It is a tumor suppressor gene, one of the most important ones in the human body. Its job is to stop cells from growing out of control, essentially acting as a brake on cancer. However, the answer gets more interesting: when p53 is mutated in certain ways, the damaged protein can flip roles and start actively driving cancer, behaving much like an oncogene. This dual nature is part of what makes p53 so central to cancer biology.
What p53 Normally Does
The p53 protein is often called “the guardian of the genome,” and the nickname fits. When your cells suffer DNA damage from things like UV radiation, toxins, or simple replication errors, p53 steps in. It can pause the cell cycle so repairs can happen, or if the damage is too severe, it triggers the cell to self-destruct through a process called apoptosis. Either way, it prevents damaged cells from dividing and passing on dangerous mutations.
This makes p53 the opposite of an oncogene. Oncogenes are genes that, when overactive or mutated, push cells to grow and divide aggressively. Tumor suppressors like p53 do the reverse: they slow growth, force quality checks, and eliminate cells that pose a threat. Cancer-related genes generally fall into one of these two categories, and p53 is firmly classified as a tumor suppressor.
How the Body Keeps p53 in Check
Because p53 is so powerful at stopping cell growth, the body tightly controls how much of it is active at any given time. The main regulator is a protein called MDM2, which latches onto p53 and tags it for destruction. MDM2 essentially sticks small molecular labels (ubiquitin) onto p53, marking it for recycling by the cell’s waste disposal system. MDM2 also physically blocks p53 from doing its job and pushes it out of the nucleus, where it needs to be to activate protective genes.
Here’s the elegant part: p53 itself turns on the gene that makes MDM2. So p53 activates its own off switch, creating a feedback loop that keeps levels balanced. When DNA damage occurs, this loop is disrupted, p53 levels rise, and the protein goes to work. Once the crisis is handled, MDM2 brings p53 back down. In some cancers, MDM2 is overproduced even without normal signals, keeping p53 suppressed and letting damaged cells survive. MDM2 overexpression has been found in sarcomas, brain tumors, melanomas, and breast cancers.
When Mutant p53 Turns Oncogenic
This is where the simple classification breaks down. TP53 mutations show up in roughly 37% of all human cancers, making it the most commonly mutated gene in cancer. Unlike most tumor suppressors, which are typically knocked out entirely, p53 mutations are usually “missense” mutations, meaning the gene still produces a full-length protein, just with a single amino acid changed. That one change can be devastating in two ways.
First, the mutant protein loses its normal tumor-suppressing abilities. It can no longer effectively stop damaged cells from dividing or trigger cell death. Second, and more unusually, the mutant protein can gain entirely new functions that actively promote cancer. Researchers call this “gain-of-function,” and it’s why some scientists describe mutant p53 as a dominant oncogene.
These gain-of-function mutations don’t just sit idle. They make tumors more aggressive, increase the likelihood of metastasis, and help cancer cells resist treatment. In lab studies, cancer cells expressing certain p53 mutants showed markedly higher resistance to common chemotherapy drugs and radiation. Knocking down the mutant p53 in those same cells made them sensitive to treatment again. The mutant protein also boosts cell migration and invasion, cooperating with other cancer-driving signals to activate genes involved in inflammation and tissue remodeling that help tumors spread.
Mechanistically, the mutant protein works by hijacking other transcription factors in the cell. It physically binds to related proteins called p63 and p73, blocking their tumor-suppressive functions. It also latches onto other gene-regulating proteins and alters their output, turning on pro-growth programs that the normal p53 would never activate.
How Common Are p53 Mutations Across Cancers
TP53 mutations are not evenly distributed. They are especially prevalent in lung, colorectal, ovarian, and breast cancers, though the specific location of the mutation within the gene varies by cancer type. Each cancer has its own “hot spots,” meaning different cancers tend to break p53 in different places. This matters because different mutations can produce mutant proteins with different gain-of-function abilities, which partly explains why cancers with p53 mutations behave so differently from one another.
Two of the most studied gain-of-function mutants are known as R175H and R273H. These specific changes have been shown to increase resistance to chemotherapy drugs like cisplatin, doxorubicin, and etoposide in both mouse cells and human lung cancer cell lines. They represent some of the clearest examples of p53 crossing the line from broken tumor suppressor to active cancer driver.
Inherited p53 Mutations and Li-Fraumeni Syndrome
Most p53 mutations happen during a person’s lifetime in individual cells. But some people inherit a broken copy of the TP53 gene from a parent, a condition called Li-Fraumeni syndrome. The cancer risk for these individuals is extraordinary. Women with the mutation reach a 50% cumulative cancer incidence by age 31, and men by age 46. By age 70, the lifetime risk approaches 100% for both sexes.
The cancers that develop tend to strike early and span multiple types. Breast cancer is the most common, with a 54% incidence in women by age 70. Soft tissue sarcomas, brain cancers, and bone cancers (osteosarcoma) are also significantly elevated. Men face a 22% lifetime risk of soft tissue sarcoma and a 19% risk of brain cancer. Li-Fraumeni syndrome is one of the starkest demonstrations of how critical p53 is for keeping cancer at bay.
Restoring p53 Function as a Treatment Strategy
Because mutant p53 is so common in cancer and actively contributes to tumor progression, there is intense interest in drugs that can restore its normal function. The strategy is to coax the misfolded mutant protein back into its proper shape so it can resume suppressing tumors. Several compounds are in clinical trials designed to do exactly this.
The most advanced is a drug called eprenetapopt (also known as APR-246), which has been tested in multiple phase 2 and phase 3 trials. In patients with certain blood cancers carrying p53 mutations, the drug combined with standard treatment produced response rates of 73% in myelodysplastic syndromes and 64% in a type of acute myeloid leukemia. Other approaches being tested include arsenic trioxide, already approved for a different type of leukemia, and a compound derived from watercress called phenethyl isothiocyanate. These trials are ongoing, and the results so far suggest that “re-folding” mutant p53 is a viable path forward.
The broader takeaway is that p53 occupies a unique place in cancer biology. It is classified as a tumor suppressor, and its normal function is unambiguously anti-cancer. But the mutant versions found in tumors can cross the line into oncogene territory, actively promoting the very disease the protein was designed to prevent. It is both, depending on whether you’re talking about the normal gene or its cancer-associated mutations.